

ERCHEM ATILLASOY, MD

PROFESSIONAL EXPERIENCE

AlloVir, Inc.
Chief Regulatory & Safety Officer

Cambridge, MA
July 2020-Present

Merck & Co., Inc.
Vice President, Global Regulatory Affairs and Clinical Safety
Executive Director and Therapeutic Area Lead, Vaccines and Infectious Disease
Therapeutic Area Lead and Senior Director, Worldwide Regulatory Affairs
Senior Director, Global Strategic Regulatory Development
Director, Regulatory Liaison, Domestic (General Medicine, Neuroscience, Oncology)

North Wales, PA
December 2012- July 2020
April 2007- November 2012
June 2003- April 2007
June 2002- May 2003
May 2001- June 2002

Sandoz and Novartis Pharmaceuticals Corporation
Medical Director, Internal Medicine, Dermatology, and Infectious Disease

East Hanover, NJ
December 1996- April 2001

EDUCATION AND TRAINING

Wistar Institute
Research Fellowship, Melanoma, Carcinogenesis and Gene Therapy
Dermatology Foundation Research Grants

Philadelphia, PA

University of Pennsylvania Medical Center, Dept. of Dermatology
Dermatology Residency

Philadelphia, PA

Yale New-Haven Hospital and Yale University School of Medicine, Dept. of Internal Medicine
Medical Internship

New Haven, CT

Yale University School of Medicine
Medical Doctorate, Farr Scholar, Class President
M.D. Thesis: PTHRP in Human Skin, Leonard Milstone, MD, Advisor

New Haven, CT

City University of New York, Brooklyn College
BA/MD Program; BA English Literature; 4.0 GPA; CUNY Belle Zeller Scholar

Brooklyn, NY

INDUSTRY ENGAGEMENT & SCIENTIFIC AFFILIATIONS

- FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC)
 - *Industry Representative selected for a 4-year term, 2019-2023*
- PhRMA Regulatory Steering Group
 - *Senior Merck Representative accountable for overall strategic direction of Science and Regulatory Advocacy activities*
- BIO BioVacRAC
 - *Senior member for Merck; Lead Strategist for Merck's preeminent role at the Annual CBER-BIO roundtable, oversight for Agenda and Merck's presentations and panel participation*
- University of Pennsylvania, Clinical Associate, Voluntary Faculty, Department of Dermatology
- Yale University and Yale School of Medicine Class Officer, Reunion Gift Chair for 2020
- Drug Information Association (DIA)
- DIA Scientific Presenter; Japan DIA (2018)
- Infectious Disease Society of America (IDSA)
- American Board of Dermatology
- American Academy of Dermatology
- American Academy of Pediatrics

- Dermatologists in Industry-member
- State of Pennsylvania, Active Medical License

SELECTED PUBLICATIONS AND PATENTS

- Amitava Mitra and Ercem Atillasoy (2012). Topical Therapies for Psoriasis. In Psoriasis, Jennifer Soung and Bonnie Koo (Ed.)
- Rich P, Harkless LB, Atillasoy ES. Dermatophyte Test Medium Culture for Evaluating Toenail Infections in Patients with Diabetes. *Diabetes Care*, May 23, 2006 (5): 1480-1484
- Atillasoy ES, (Contributor and author) "Skin Cancers and Non-Cancerous Skin Growths," Merck Manual, Home Edition, 2003 edition
- Elewski B, Leyden J, Atillasoy ES. The Infection Confirmation Survey (Onychomycosis). *Archives of Internal Medicine* 2002.
- Jansen DA., Asgari MM, Atillasoy ES, LM Milstone. Clinical and in Vitro Responses of Bilayered Skin Construct (Graftskin) to Meshing. *Arch Dermatol*; June 2002. 138 (6) pp 843-844
- Atillasoy ES, et al. The Role of Anti-Fungal Agents in Immune-Compromised Patients. *Postgraduate Medicine* (in preparation) 2001.
- Hazen KC, Moon AE, and Atillasoy ES. Susceptibility Testing of Anti-Dermatophyte Agents Using a Human Skin Construct. *J Clin Microbiol* 2001.
- Rich P, Karchmer AW, Atillasoy ES. The Efficacy and Safety of Terbinafine in Diabetic Patients: A Multicenter Trial in Toenail Onychomycosis. *Clin Therapeutics* 2001.
- Atillasoy ES, Santoro A, Weinberg JM. Lymphoedema Associated with Kaposi's sarcoma. *J Eur Acad Dermatol Venereol*. July 2001. 15 (4)
- Atillasoy ES (Editor). Use of Terbinafine in the in HIV Positive and Diabetes Patients with Dermatophytosis. *Cutis* (Supplement) July 2001. Vol. 68 1-40S.
- Smith EB, Stein LF, Fivenson DP, and Atillasoy ES. The Safety of Terbinafine in Patients Over the Age of 60 Years: A Multicenter Trial in Onychomycosis of the Feet. *Int J Dermatol*. 2000 Nov; 39(11):861-4.
- Atillasoy ES (editor) Current and Investigative Uses of Graftskin in Wound Care. *Journal Suppl Wounds*. 2000; 12 (5 Suppl A): 1A-79A.
- Atillasoy, ES, Overview of Atopic Dermatitis. Editor Monograph and Slide Set, Novartis Pharmaceuticals, June 1998 – 2000
- Sauter E, Klein-Szanto AJP, Atillasoy ES, Montone KT, Goodrow T, Binder RL, Seykora JT, Herlyn M. Ultraviolet B-Induced Squamous Epithelial and Melanocytic Cell Changes in a Xenograft Model of Cancer Development in Human Skin. *Molecular Carcinogenesis* 23: 168-174, 1998.

- Atillasoy ES, Soballe P, Elenitsas R, Nesbit M, Seykora J, Herlyn M. UVB Induces Atypical Melanocytic Lesions and Melanoma in Human Skin. *Am J Pathology* 152: 1179-1186, 1998
- Weinberg JM, Baxt RD, Egan CL, Rook AH, Atillasoy ES, Regsdale BD. Mucormycosis in a Patient with Acquired Immunodeficiency Syndrome. *Arch Dermatol.* 1997 Feb; 133(2):249-51. No abstract available.
- Atillasoy ES, Elenitsas R, Soballe P, Herlyn M. UVB Induction of Epithelial Tumors in Human Skin Using a RAG-1 Mouse Xenograft Model. *J Invest Dermatol* December 1997.
- Weinberg JM, Baxt RD, Egan CL, Rook AH, Atillasoy ES, Ragsdale BD. Mucormycosis in a Patient with Acquired Immunodeficiency Syndrome. *Arch Dermatol.* Feb 1997. 133 (2).
- Atillasoy ES, Santoro A, Puri N. Cutaneous Drug Reactions. *Asian Clinics of Dermatol* Vol 2, December 1996.
- Egan C, Atillasoy ES, and Werth V. Case Report: Vulvar Melanoma. CD-ROM, *Am Acad of Dermatol*, 1996.
- Manders S, Heymann WR, Atillasoy ES. Recurrent Toxin-mediated Perineal Erythema. *Arch of Dermatol* 132: 57-60, 1996.
- Atillasoy ES, Weinberg J, et al. Adenocarcinoma of the Breast Presenting as a Keloid. *J. Geriatric Dermatol*, 3(5): 183-185, 1995
- Atillasoy ES. Multicentric Reticulohistiocytosis: Case Report. CD-ROM, *Am Acad of Dermatol*. 1994
- Gaich G, Orloff JJ, Atillasoy ES, Burtis WJ, Ganz MD, Stewart AF. Amino-terminal Parathyroid Hormone-Related Protein: Specific Binding and Cytosolic Calcium Responses in Rat Insulinoma Cells. *Endocrinology* 123(3): 1402-9, 1993
- Schwartz PM, Barnett SK, Atillasoy ES, Milstone LM. Methotrexate Induces Differentiation of Human Keratinocytes. *Proc Natl Acad Sci* 89(2): 594-8, 1992.
- Atillasoy ES, Burtis WJ, Milstone LM. Immunohistochemical Localization of Parathyroid Hormone-related protein (PTHrP) in Normal Human Skin. *J Invest Dermatol* 96(2); 277-80, 1991.
- Atillasoy ES. Humanities in Medicine. *JAMA* 262: 9, 1260, 1989
- Nelson JC, Atillasoy ES, Mazure C, Jatlow PI. Hydroxydesipramine in the Elderly. *J Clin Psychopharmacol* 8(6): 428-33, 1988
- Patent Approval via Novartis Pharmaceuticals, Terbinafine for the treatment of Fungal Sinusitis